Mandate

Vinge advises Skåne Dairy in connection with its sale of shares in ProViva AB to Danone and formation of a joint venture

September 29, 2010

Vinge has advised Skåne Dairy in connection with the sale of 51 per cent of the shares in ProViva AB to Danone. Pursuant to the terms of the agreement, the parties’ joint ownership of the company will commence at the end of 2010 and Danone will thereafter increase its stake in ProViva over the course of an 11-year period culminating in the company ultimately becoming wholly-owned by Danone. ProViva is a health drink containing a bacteria called Lactobacillus plantarum 299v, which was developed by Skåne Dairy in co-operation with Probi. The Danone Group is one of the world’s leading providers of fresh dairy products and its products include the Swedish registered brands Actimel, Activia and Danio.

Vinge’s team consisted of partner Björn Mullaart together with associates Kristian Ford, Anna Jonsson and Markus Larsson. Partner Ingela Malmborg and associate Therese Lindholm provided employment law advice and Ingela Malmborg together with associate Mathias Lindquist provided environmental law and permit compliance advice.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026